The AMPK signaling pathway is a potential therapeutic target for NAFLD, as it modulates lipid metabolism by regulating the ACC/SREBP-1c/PPARα pathway [61,62]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.